Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
NCT00009776
Unknown
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with cyclosporine and paclitaxel may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy combined with paclitaxel and cyclosporine in treating patients who have recurrent or refractory non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2013
Locations: University of California Davis Cancer Center, Sacramento, California
Conditions: Lymphoma
Register for Updates
Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer
NCT00138151
Terminated
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sometimes when chemotherapy is given, it does not stop the growth of tumor cells. The tumor is said to be resistant to chemotherapy. Giving isotretinoin and interferon alpha-2b together with paclitaxel may reduce drug resistance and allow the tumor cells to be killed. PURPOSE: This phase II trial is studying how well... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/17/2013
Locations: Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey +5 locations
Conditions: Cervical Cancer
Register for Updates
Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer
NCT00392392
Completed
This trial combines trastuzumab and bevacizumab monoclonal antibodies, with ABI-007 and carboplatin, as neoadjuvant therapy in previously untreated locally advanced breast cancers demonstrating HER2 gene amplification. It is hoped that this novel combination will result in increased pathologic response rates that will translate into long term outcome improvements in HER2 positive patients with locally advanced breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/17/2013
Locations: Florida Cancer Specialists, Fort Myers, Florida +5 locations
Conditions: Breast Cancer
Register for Updates
Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00024310
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Folic acid may protect normal cells from the side effects of chemotherapy and may increase the effectiveness of chemotherapy by making tumor cells more sensitive to the drug. Lometrexol may stop the growth of tumors by blocking one of the enzymes necessary for cancer cell growth. Combining chemotherapy with folic acid and lometrexol may kill more tumor cells. PURPOSE: Phase I... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2013
Locations: Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California
Conditions: Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer
NCT00983424
Completed
The purpose of this research study is to evaluate the safety of therapy with nab-paclitaxel and CsA and if the addition of Cyclosporine A (CsA) to nab-paclitaxel helps stop cancer cells as well as or better than nab-paclitaxel alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2013
Locations: Northwestern University, Northwestern Medical Faculty Foundation, Chicago, Illinois
Conditions: Metastatic Breast Cancer
Register for Updates
A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
NCT00970580
Completed
The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2013
Locations: Resesarch Site, Los Angeles, California +2 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer
NCT00002939
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan and paclitaxel in treating patients with metastatic or recurrent cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/04/2013
Locations: University of Chicago Cancer Research Center, Chicago, Illinois
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis
NCT00002949
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy with may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of chemotherapy with vinorelbine and paclitaxel plus radiation therapy in treating patients with advanced cancer arising in the pelvis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/04/2013
Locations: University of Chicago Cancer Research Center, Chicago, Illinois
Conditions: Bladder Cancer, Cervical Cancer, Endometrial Cancer, Vaginal Cancer
Register for Updates
Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
NCT00005635
Completed
RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of two different regimens of trastuzumab plus paclitaxel in treating wom... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/16/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Breast Cancer
Register for Updates
Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma
NCT00008021
Unknown
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy, cyclosporine, and paclitaxel follow... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2013
Locations: University of California Davis Cancer Center, Sacramento, California
Conditions: Lymphoma
Register for Updates
Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer
NCT00002662
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel is more effective than docetaxel for breast cancer. PURPOSE: Randomized phase III trial to study the effectiveness of paclitaxel or docetaxel in treating women with stage IIIB or metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/01/2013
Locations: Montclair Regional Cancer Center, Birmingham, Alabama +31 locations
Conditions: Breast Cancer
Register for Updates
A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer
NCT00583830
Completed
The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with carboplatin and paclitaxel as first line therapy in subjects with advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2013
Locations: Birmingham Hematology and Oncology Associates, LLC, Birmingham, Alabama +32 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates